The major obstacle to successful bone marrow transplantation (BMT) is graft-versus-host disease (GVHD). Vitamin D analogs have shown their efficacy in solid organ transplantation. The purpose of this study was to investigate the suitability of a novel vitamin D analog, MC1288, in the prevention of acute GVHD in a rat BMT model. Allogeneic BMT were performed from Lewis to BN rats (n = 18). The animals were divided into four groups: an untreated control group, MC1288, cyclosporin A (CsA), and MC1288 + CsA-treated groups. Rats were harvested for histology and immunohistochemistry on day 20 after BMT. Histological changes for GVHD in liver, skin, and spleen were scored. Positivity in immunostaining was quantified as the number of positive cells/high power field. Treatment with MC1288 decreased clinical signs of GVHD compared with untreated or CsA-treated rats. Histological manifestations of GVHD, expressed as mean total increment, were significantly lower (1.4 ± 0.5) in MC1288 than in untreated (5.0 ± 1.6) or CsA (3.5 ± 1.0) groups. Combining MC1288 and CsA further improved histology (1.1 ± 0.6). The expression of CD4, CD8, MHC class II, interleukin-2 receptor, nitric oxide 2, and NKR-P1A (NK cells) positivity was significantly decreased in the liver and skin of BMT rats by MC1288. MC1288 was effective in preventing clinical and histological signs and symptoms of GVHD. This novel vitamin D analog could be used as an immunomodulating agent in BMT. The major obstacle in using natural vitamin D or its early analogs for treatment has been hypercalcemia before therapeutic concentrations could be reached. 9, 10 This problem has now been solved with novel analogs with lesser calcemic activity.
thickening associated with transplant arteriosclerosis, or chronic rejection, in a rat aortic transplant model. 7 In addition to their immunosuppressive effects, we and others have shown that vitamin D analogs have anti-leukemic effects both in vitro and on de novo patient samples. 8 The major obstacle in using natural vitamin D or its early analogs for treatment has been hypercalcemia before therapeutic concentrations could be reached. 9, 10 This problem has now been solved with novel analogs with lesser calcemic activity. 7, 8 MC 1288 is a 20-epi-1,25(OH) 2 D 3 , differing from 1,25(OH) 2 D 3 by altered stereochemistry of the methyl group at carbon 20 in the side chain of the molecule ( Figure 1) . We have previously shown that MC1288 is well tolerated in rats in vivo. It did not induce hypercalcemia during the first month of treatment although in 3 months, the serum calcium level increased by 30%. 7 The purpose of this study was to investigate the suitability of MC1288 in the prevention of acute graft-versushost disease (GVHD) in a rat bone marrow transplantation (BMT) model. Here, we studied the effects of MC1288 on the clinical course and histological manifestations of acute GVHD after allogeneic BMT.
Materials and methods

Bone marrow transplantation (BMT)
Allogeneic bone marrow transplantations were performed using adult Brown Norway (BN; RT1 l ) rats as recipients and 10-week-old Lewis (LEW; RT1 n ) rats as bone marrow cell donors. The cells were collected by flushing the femurs with saline. The recipient animals were irradiated with 960 rad (Varian Climac 600c, 6 MV photon irradiation, distance 120 cm, field size 40 × 40 cm 2 ) prior to BMT. After 24 h, 60-80 × 10 6 mononuclear bone marrow cells from LEW rats were injected into BN recipients.
All rats were purchased from the Laboratory Animal Center (University of Helsinki, Helsinki, Finland), and they received humane care in compliance with the Principles of Laboratory Animal Care and the Guide for the Care and Use of Laboratory Animals prepared and formulated by the National Institute of Health (NIH Publication No. 86-23, revised 1985). 
Medication
The animals (n = 18) were divided into four groups with the following treatments: vitamin D analog MC1288 (Leo Pharmaceutical Products, Ballerup, Denmark) 0.1 g/kg/ every 2nd day i.p., cyclosporin A (Neoral; Novartis, Basel, Switzerland) (CsA) 5 mg/kg/daily, p.o. resulting in trough levels of 385 ± 149 nmol/ml (comparable to clinical levels), MC1288 0.1 g/kg/every 2nd day, and CsA 5 mg/kg/day together, and a control group receiving no immunosuppressive treatment. CsA, which is used as a standard treatment in BMT patients, provided a secondary control group. Sulfonamide and trimetoprime (Cotrim; Merckle, Blaubeuren, Germany) was administered for 10 days i.p. as infection prophylaxis to all the recipients.
Histological analysis
To study histological manifestations of GVHD, the animals were sacrificed 20 days after transplantation. After BMT from Lewis to BN rat strain, the strongest histological changes are observed in the liver, a model parenchymal target organ for acute GVHD in this strain combination.
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Skin, liver and spleen were removed, fixed in 4% formalin solution and processed for histology. Paraffin sections were stained with Mayer's hematoxylin and eosin (HE). Histologic features of acute GVHD were graded independently by two investigators (I Pakkala and E Taskinen) on a 0 to 4 scale using previously published grading systems. [11] [12] [13] [14] Briefly, skin manifestations were graded for their focal or diffuse vacuolar degeneration of epidermal basal cells (grade 1), diffuse spongiosis and dyskeratosis or eosinophilic degeneration of epidermal cells (grade 2). In grade 3, there were all the above changes as well as partial separation of the dermal-epidermal junction and in grade 4, loss of epidermis was seen. Liver manifestations were graded for small lymphocyte and plasma cell infiltration into the portal tracts, voluminous Kupffer cells, portal and/or central venous endothelialitis, and evidence of bile duct injury or cholangitis. Spleen manifestations were graded for fibrosis and hypocellularity with an increase in siderophages and megakaryocytes. The results were expressed as the mean total increment (MTI) for each of the organs and summarized resulting in a maximum score of 12 reflecting the severity of acute GVHD.
Statistical analysis was performed using the nonparametric Kruskal-Wallis test with Dunn correction for multiple comparisons, where P Ͻ 0.05 was considered significant.
Immunostaining
Serial frozen sections (4-6 m, n = 12/staining) were immunostained using a standard multi-layer method. Briefly, after acetone and chloroform fixation of the slides the non-specific staining was blocked with appropriate 1.5% non-immune serum (Vector Laboratories, Burlingame, CA, USA). For a primary antibody we used CD4 (W3/25; Harlan Sera-Lab, Belton, UK), CD8 (OX8; SeraLab), MHC class II common determinant (OX6; Sera-Lab), nitrate oxide synthase 2 (NOS2) (M-19; Santa Cruz Biotechnology, Santa Cruz, CA, USA), and NKR-P1A (10/78; PharMingen, San Diego, CA, USA). The secondary antibody was biotinylated and followed by an avidin-biotin complex (Vectastain Elite ABC Kit; Vector Laboratories) and chromogen 3-amino-9-ethylcarbazole (AEC; Sigma, St Louis, MO, USA) containing 0.4% hydrogen peroxidase, yielding a brown-red reaction product. The specimens were counter-stained with hematoxylin.
Immunostaining was evaluated by two observers and the results were expressed as a mean number of positive cells/visual field at magnification ×1000. The data are given as mean ± s.d. Statistical analysis was performed using the non-parametric Kruskall-Wallis test with Dunn correction for multiple comparisons, where P Ͻ 0.05 was considered significant.
Results
MC1288 effectively suppressed GVHD-related dermatitis
Acute GVHD manifests first and most commonly in the skin. After allogeneic BMT, the untreated control group showed signs of dermatitis in the paws and the erythema of the ears from day 5 onward. The animals began to lose hair on day 11. The CsA-treated group showed similar, although milder, signs of GVHD within the same timeframe. Rats that received MC1288 or the combined treatment with CsA showed none of the above signs of GVHD.
All animals developed mild diarrhea by day 9. In addition, they lost some weight. Before BMT, the recipient rat weights were 255 ± 40 g, but decreased to 191 ± 14 g in the untreated, to 219 ± 25 g in the CsA, to 228 ± 39 g in the MC1288 and to 225 ± 27 g in the combined treatment group. Taken together, MC1288 effectively suppressed the clinical signs of GVHD, ie dermatitis, weight loss and hair loss in rats after BMT.
MC1288 suppressed histological manifestations of GVHD
Within 20 days after BMT, the untreated rats developed classical signs of GVHD in various organs (Figure 2 ). In the liver, the portal tracts were enlarged and affected by moderate inflammatory infiltration and edema, and there was mild cholangitis. In contrast, in the MC1288-treated animals the portal tracts were only slightly enlarged with little to no inflammation or destruction, but with mild inactive fibrosis in the background.
In the untreated rats, the ear skin manifestations of GVHD included marked affected epidermis with intercellular edema, destructed basal cells and some intraepithelial lymphocytes. In contrast, in the ear skin of the MC1288-treated animals, there was no inflammation, edema or destruction. However, some mild degeneration of the basal layer was observed.
normal liver normal skin normal spleen untreated liver untreated skin untreated liver MC1288 liver MC1288 skin MC1288 spleen Figure 2 Representative microphotographs of the liver, skin, and spleen after BMT. Treatment with MC1288 significantly decreased pathological alterations: the enlarged portal tracts, inflammatory infiltration and edema in liver. In the skin, GVHD included epidermis with intercellular edema, destructed basal cells and some intraepithelial lymphocytes. In the spleen, there was a loss of normal splenic architecture, fibrosis, depletion of lymphocytes in white pulp, and the appearance of megakaryocytes and siderophages in the red pulp. H & E stainings, original magnifications ×400 and ×600.
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In the spleen of the untreated rats, a complete loss of normal splenic architecture of white and red pulp was seen. There were pronounced reactive alterations including fibrosis, depletion of lymphocytes in the white pulp and the appearance of megakaryocytes and siderophages in the red pulp. In contrast to manifestations in the liver and skin, the MC1288-treated animals showed similar, but less pronounced, alterations in the red and white pulp. Several siderophages but no megakaryocytes were found in the red pulp.
In the group that received MC1288 and CsA combined, the histological signs of GVHD were essentially similar to that of MC 1288 alone (data not shown). In contrast, CsA alone at the dose of 5 mg/kg/day had little effect on preventing the GVHD lesions (data not shown).
To assess the degree of GVHD, we graded these histologic alterations of GVHD in the skin, liver and spleen in different treatment groups as a mean total increment ( Figure 3) . The groups treated with MC1288, either alone, or in combination with CsA, had a significantly lower mean total increment (1.4 ± 0.5 and 1.1 ± 0.6, respectively) compared to the untreated animals (5.0 ± 1.6, P Ͻ 0.001 for both). CsA alone was slightly beneficial (3.5 ± 1.0, P = NS), albeit not significantly, compared to the untreated rats.
Taken together, these results show that a novel vitamin D analog, MC1288, was effective in preventing histological manifestations of acute GVHD in the skin, liver and spleen. MC1288 was more effective than CsA alone in preventing GVHD, but when combined these two drugs may even have additive effects. 
MC1288 suppressed immune cells more effectively than CsA in BMT
To study the effect of MC1288 on effector T cells and macrophage activation, immunohistochemistry was performed on frozen sections of liver and skin and quantified. The results are summarized in Table 1 .
In the liver, MC1288 markedly suppressed CD4-positive cells. The effect was more pronounced when combined with CsA. MC1288 and CsA were equally effective in sup- Table 1 Expression of inflammatory markers in liver and skin after BMT pressing CD8-positive cells. However, when the animals were treated with the combination of these drugs, no CD8-positive cells were found. The findings were similar in the MHC class II expressing cells. IL-2 receptor (IL-2R) expression was strongly suppressed after MC1288 treatment as well as after CsA and CsA + MC1288 treatments. Nitric oxide synthase 2 (NOS2) in the liver was suppressed in all treatment groups. The expression of natural killer cells (NKR-P1A) was markedly suppressed with the combination therapy, whereas MC1288 alone had a lesser effect. The number of NK cells in the CsA group was slightly elevated compared to the untreated group. To summarize, MC 1288 effectively suppressed CD4, CD8, MHC class II, IL-2R, and NOS2 expression in the liver. In the skin, MC1288 markedly suppressed the expression of CD4-positive cells but the effect was more pronounced when combined with CsA. CD8-positive cells were totally suppressed by MC1288. CsA did not have a significant effect on CD8 cells in the skin. The MHC II expression in the skin was very similar to the liver. MC1288 proved to be very effective in suppressing class II expression with a further improved effect in combination therapy. IL-2R expression was also significantly suppressed in the skin after MC1288 treatment. NOS2 expression in the skin was markedly decreased by MC1288. Interestingly, in the skin, CsA treatment caused an unexpected elevation of NOS2 expression as opposed to the effect in the liver. This finding was concordant with the fact that combination treatment showed more positivity than MC1288 alone. NK cells were absent in both of the MC1288-treated groups and the CsA alone group was also significantly lower. In summary, MC1288 effectively suppressed CD4, CD8, MHC class II, IL-2R, NKR-P1A, and NOS2 expression in the skin 20 days after allogeneic BMT.
Discussion
We report here several new findings. First, a novel vitamin D analog, MC1288, either alone or in combination with CsA, prevented clinical signs of GVHD after allogeneic bone marrow transplantation. Second, the histological features of GVHD, ie epidermal vacuolar degeneration, portal small lymphocyte infiltration, bile duct injury, edema, fibrosis, and appearance of megakaryocytes in the spleen, were significantly suppressed in MC1288-treated groups. Third, MC1288 effectively suppressed CD4-and CD8-positive T cells, NK cells, MHC class II, IL-2R and NOS2 expression in the skin and liver, suggesting that MC1288 acts through T and NK cell and macrophage suppression.
The immunopathogenesis of GVHD can be divided into three phases: (1) recipient conditioning, (2) donor T cell activation and (3) inflammatory effectors. 15 In phase I, host conditioning including total body irradiation or chemotherapy leads to damage and activation of host tissues, which causes increased secretion of inflammatory factors such as LPS, tumor necrosis factor ␣ (TNF-␣) or interleukin-1 (IL-1) and IL-6.
In phase II, host alloantigens activate donor T cells that differentiate and proliferate into Th1-and/or Th2-type subsets. Specifically, Th1-type cytokine (IFN-␥ and IL-2) responses have been postulated to be responsible for GVDH through controlling and amplifying immune cells: CD4 + and CD8 + T cells, NK cells and monocytes. 15 Recently, it has been shown that both Th1-and Th2-type cytokines mediate acute GVHD with distinct end-organ targets. 16 Using STAT4 gene-deficient mice that induce a Th2-type immune response as BMT donors mainly caused liver and skin manifestations of acute GVHD in the recipients. In contrast, intestinal manifestations of GVHD were the major observation in the recipients that received BMT from STAT6 gene-deficient mice mounting a Th1-type cytokine response. This study clearly demonstrated that both Th1 and Th2 responses are necessary for the development of GVHD. Our study showed that MC1288 effectively decreased the number of CD4 + and CD8 + cells and IL-2 receptor expression in the liver and skin. Whether MC1288 selectively down-regulated either Th1-or Th2-type cytokine producing cells, or both of them equally, remains open.
Phase III of acute GVHD culminates in the effector functions that lead to full spectrum of deleterious effects including cachexia and target cell destruction in different organs. 15 Mediators of these lesions include inflammatory cytokines and nitric oxide, macrophages/monocytes, NK cells, specific anti-host cytotoxicity mediated by CTL through Fas and perforin apoptotic pathways. Here, we have shown that MC1288 effectively decreased both NK cell (NKR-P1A) and NOS2 expression in the liver and skin after BMT suggesting that MC1288 not only influences phase II T cell activation but also suppresses the effector phase.
All in all, the vitamin D analog MC1288 down-regulated both the donor T cell activation (phase II) and inflammatory effector mechanisms (phase III) of acute GVHD after major mismatched allogeneic BMT. MC1288 was even more effective in preventing GVHD when combined with CsA.
The disadvantages of the currently used pharmacological agents CsA, prednisone, methotrexate, and FK506 are that they produce generalized immunosuppression and have a negative influence on the beneficial graft-versus-leukemia effect. In contrast to these 'traditional' immunosuppressive drugs, vitamin D analogs have also demonstrated anti-leukemic effects in vivo and in vitro. 8, 9, 17 However, different vitamin D analogs vary significantly in their immunosuppressive, anti-leukemic, and calcemic properties, 10 and therefore, further studies are required to assess the most suitable analog for clinical studies.
In conclusion, in this study we showed that MC1288 was effective in preventing clinical and histological signs and symptoms of GVHD. Further improvement was achieved when MC1288 was combined with CsA which was ineffective alone. Our results are encouraging in taking these novel vitamin D analogs further to clinical trials.
